- November 2014
Carl June on the efficacy of CAR-T cells in treating leukaemia.
- October 2014
News from ESMO 2014 with Solange Peters and Alexander Eggermont.
- September 2014
Discussing how healthcare systems can meet the needs of cancer survivors.
- July/August 2014
Sophie Postel-Vinay on new recommendations for phase 1 trials.
- June 2014
Hans Clevers on important research into stem cells in normal gut tissue.
- May 2014
Carolyn Taylor and Paul McGale find evidence to clarify guidelines for radiotherapy after mastectomy.
- April 2014
Richard Sullivan and Ajay Aggarwal on how physicians can tackle the issue of affordability in cancer care.
- March 2014
The 1st EORTC Cancer Survivorship Summit addressed the practical problems faced by cancer patients.
- February 2014
Charles Swanton on a study that maps genetic changes in cancers over time.
- January 2014
Presidents of various cancer societies make predictions for the coming year.
EJC News Focus – July/August 2013
Good times and bad for clinical trials research
Functional imaging and other new technologies are revolutionising the landscape for cancer research. The knowledge imparted by these techniques – from genetics, epigenetics, proteomics and so on – should mean that we're entering a new phase in our understanding and therefore treatment of the disease.
Yet many of the same old obstacles between lab and clinic remain. Clinical trials research is still dogged by regulatory issues, funding is a perennial problem, agreement on data protection has yet to be reached.
EORTC President Roger Stupp calls for the patient's point of view to move centre stage. While rarified discussions and debates take place, patients are waiting for clinical trials to be set up and for results to be integrated into clinical practice, he says. Here, he tells Helen Saul that speedy activation of trials is needed, as is funding for academic trials and, overall, a common sense approach which would allow the questions most relevant to patients, to be addressed.